Delphia (USA)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Delphia (USA)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,486	Closed	-$206K	–	305
2022 Q2	$206K	Buy	+2,486	New	+$198K	0.14%	274

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Delphia (USA)'s BMRN Position: Q3 2022 in Review

Delphia (USA) sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 2,486 shares — an estimated $206K sold.

Delphia (USA) first reported a position in BMRN in Q2 2022 and held it in 1 quarter. The position peaked at $206K in Q2 2022. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Delphia (USA) reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 2,486 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $206K.
Delphia (USA) first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s BioMarin Pharmaceuticals position peaked at $206K in Q2 2022.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.